Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Tuberous Sclerosis 3Seizures 3Sturge-Weber Syndrome 2Tuberous Sclerosis 2 1Tuberous Sclerosis 1 1Spasms, Infantile 1Lennox Gastaut Syndrome 1Glioblastoma 1Epilepsy 1Epilepsies, Myoclonic 1Drug Resistant Epilepsy 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Breast Neoplasms 1Arthralgia 1Anxiety Disorders 1

Interventions

Temozolomide 115Bevacizumab 72Radiotherapy 52Radiation 23Erlotinib Hydrochloride 13Lomustine 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Vorinostat 10Nivolumab 10Surgical Procedures, Operative 9Irinotecan 9Sorafenib 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 7Immunoglobulin G 7Everolimus 7Drug Therapy 7Disulfides 7Radiosurgery 6Granulocyte-Macrophage Colony-Stimulating Factor 6Carmustine 6antineoplaston AS 2-1 5antineoplaston A10 5Sirolimus 5Cilengitide 5veliparib 4veledimex 4temsirolimus 4selinexor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Glioblastoma × Cannabidiol × Clear all
NCT05753007 2026-03-16

A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients

Mclean Hospital

Phase 2 Terminated
2 enrolled 13 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡